Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $24.50

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been given a consensus recommendation of “Hold” by the eleven analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $24.50.

A number of analysts have issued reports on ATXS shares. Lifesci Capital downgraded shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. HC Wainwright lowered Astria Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 16th. JMP Securities reiterated a “market perform” rating on shares of Astria Therapeutics in a research note on Wednesday, October 15th. Oppenheimer lowered shares of Astria Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Astria Therapeutics in a research note on Wednesday, October 8th.

Astria Therapeutics Trading Down 1.5%

Shares of ATXS opened at $12.89 on Monday. The firm has a 50-day moving average price of $12.71 and a 200 day moving average price of $9.20. Astria Therapeutics has a 12-month low of $3.56 and a 12-month high of $13.29. The firm has a market capitalization of $735.76 million, a P/E ratio of -6.02 and a beta of 0.01.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The company had revenue of $0.71 million for the quarter, compared to analysts’ expectations of $10.67 million. Equities research analysts predict that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Trading of Astria Therapeutics

Institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC increased its position in shares of Astria Therapeutics by 22.3% during the third quarter. Farther Finance Advisors LLC now owns 6,693 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,222 shares in the last quarter. Sio Capital Management LLC increased its position in Astria Therapeutics by 1.0% during the second quarter. Sio Capital Management LLC now owns 318,256 shares of the biotechnology company’s stock worth $1,706,000 after buying an additional 3,151 shares during the period. Russell Investments Group Ltd. lifted its stake in Astria Therapeutics by 10,311.8% in the third quarter. Russell Investments Group Ltd. now owns 3,540 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 3,506 shares during the last quarter. American Century Companies Inc. lifted its stake in Astria Therapeutics by 8.3% in the second quarter. American Century Companies Inc. now owns 56,442 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 4,335 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Astria Therapeutics by 3.1% in the first quarter. Wellington Management Group LLP now owns 152,611 shares of the biotechnology company’s stock valued at $815,000 after acquiring an additional 4,562 shares during the period. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.